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Abstract
Neutrophils, the most abundant human immune cells, are rapidly recruited to sites of infec-
tion, where they fulfill their life-saving antimicrobial functions. While traditionally regarded as
short-lived phagocytes, recent findings on long-term survival, neutrophil extracellular trap
(NET) formation, heterogeneity and plasticity, suppressive functions, and tissue injury have
expanded our understanding of their diverse role in infection and inflammation. This review
summarises our current understanding of neutrophils in host-pathogen interactions and dis-
ease involvement, illustrating the versatility and plasticity of the neutrophil, moving between
host defence, immune modulation, and tissue damage.
Neutrophil’s Life Cycle
Granulopoiesis
Neutrophils are the predominant immune cell population in human blood, where they patrol
and protect us from pathogens, and diseases with neutropenia show that they are indispensable
for controlling bacterial and fungal infections. Neutrophils develop in the bone marrow from
haematopoietic stem cells in a process called “granulopoiesis” and mature neutrophils are char-
acterised by their segmented nucleus and granules that are filled with>700 proteins [1]. Bone
marrow neutrophil lineage cells can be divided into three compartments: (i) the stem cell pool
composed of hematopoietic stem cells and pluripotent progenitors; (ii) the mitotic pool com-
posed of proliferating, lineage-committed myeloblasts, promyelocytes, and myelocytes; and
(iii) the post-mitotic pool composed of metamyelocytes, band cells, and mature neutrophils.
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Post-mitotic bone marrow neutrophils constitute 95% of the neutrophils in the body [2,3] and
this reserve is easily mobilized and recruited rapidly to sites of infection.
Granulocyte colony-stimulating factor (G-CSF) is the predominant factor regulating the
neutrophil’s life cycle by increasing cell proliferation, survival, differentiation, and trafficking/
mobilization. Mice lacking G-CSF or its receptor have a profound, but not absolute, neutrope-
nia in bone marrow and blood [2,4,5]. However, these mice can still produce mature neutro-
phils in steady state and increase their production and mobilization in “emergency” situations,
indicating that other signals can provide partial or complete compensation [6]. Moreover,
G-CSF induces proliferation and expression of anti-apoptotic proteins and regulates chemo-
kine expression [7,8]. However, the precise mechanisms by which G-CSF signals regulate mi-
totic and post-mitotic neutrophils are not fully understood. Maintenance of neutrophil
numbers is further regulated by phagocytosis of apoptotic neutrophils by macrophages, a pro-
cess termed “efferocytosis.” Efferocytosis reduces the production of interleukin (IL)-23 and
IL-17 and dampens G-CSF production [9]. G-CSF thus regulates the neutrophil life cycle at
multiple levels and, consequently, has become an important therapeutic agent for neutropenic
diseases, as discussed below. Recently, autophagy has been reported as a negative regulator of
neutrophil development in the bone marrow [10].
Mobilization and trafficking
Chemokines orchestrate the balance between neutrophil release and retention. Bone marrow
stromal cells produce C-X-C-motif chemokine ligand (CXCL) 12 that binds to C-X-C-motif
chemokine receptor (CXCR) 4, leading to neutrophil retention, while release is mainly mediat-
ed by CXCR2 [11]. Pharmacologic CXCR2 inhibition in healthy humans, using ozone- or LPS-
induced inflammation models [12–15], or in patients with severe asthma [16] or cystic fibrosis
(CF) [17] showed that CXCR2 inhibition is safe and decreases neutrophilic inflammation in
the airways.
Clearance of apoptotic neutrophils by macrophages, a mechanism involving liver X receptor
(LXR), is essential for immune homeostasis and impaired clearance of apoptotic neutrophils
has been linked to autoimmune disease [18–20]. Recent murine studies have extended this con-
cept by highlighting the role of the bone marrow as a site of neutrophil clearance [21]. Intrigu-
ingly, homing of senescent neutrophils back to the bone marrow was found to regulate the
circadian release of hematopoietic progenitors into the circulation [22]. However, the relevance
of this circadian mechanism for neutrophil homeostasis in humans remains debatable. Anoth-
er layer of complexity has been added by the concept of reverse neutrophil migration from pe-
ripheral organs back into the bloodstream. Reverse transmigration has been first observed in
endothelial cells in vitro [23], and in mice in vivo [24], and has then been defined as a novel
mechanism of inflammation resolution in zebrafish models [25]. Despite these fascinating
mechanistic insights, their relevance for human diseases remains to be defined.
Released neutrophils are proposed to disseminate in the periphery into circulating and mar-
ginated neutrophil pools. The latter refers to neutrophils adherent to endothelial cells in the
spleen, liver, bone-marrow, and the lung that can be recovered by exercise and adrenaline [26].
While a recent study highlights the importance of the pulmonary marginated pool in mice
[27], its role in humans, at least under homeostatic conditions, remains questionable since the
injection of non-primed autologous neutrophils did not lead to a significant retention in the
pulmonary vasculature [28]. Further studies are required to shed more light on the marginated
neutrophil pool in man and mice.
The traditional paradigm of neutrophils as short-lived immune cells has been challenged by
in vivo-labelling studies, demonstrating a life span of 5.4 days for human neutrophils [29], ten
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times longer than previously estimated, and suggesting that neutrophils shape immune re-
sponses beyond rapid host–pathogen interactions. However, alternative explanations have
been proposed [30,31] and there is no broad consensus yet regarding the life span of neutro-
phils in humans. Furthermore, in vivo-labelling studies are required to solve these controver-
sies and to gain deeper insight into the neutrophil’s life span, particularly under infectious
disease conditions.
Neutrophil serine proteases, serpins, and neutrophil survival
Amongst the broad armamentarium that neutrophils carry in their granules, neutrophil serine
proteases directly kill microbes and inactivate bacterial toxins [32,33]. Excessive host tissue
damage and inflammation driven by the uncontrolled activity of these proteases (namely elas-
tase, proteinase-3, and cathepsin G) is counterbalanced by endogenous serine protease inhibi-
tors (“serpins”) [34]. Besides protecting the body from free and harmful proteolytic activities,
recent studies demonstrate that serpins have an unexpectedly broader role in regulating neu-
trophil survival. This novel function was first hinted at by mice lacking the intracellular inhibi-
tor Serpinb1a, which showed reduced neutrophil survival and severe bone marrow
neutropenia [35], rendering these mice susceptible to bacterial and viral lung infections
[36,37]. Further studies showed that Serpinb1a is critical for maintaining neutrophil survival
by blocking cell-intrinsic death mediated by cathepsin G and proteinase-3 [38,39].
Neutrophil–Pathogen Interactions
Recent findings have substantially expanded our view on the repertoire of antimicrobial effector
functions of the neutrophil in host–pathogen interactions. Beyond phagocytosis, neutrophils
employ neutrophil extracellular traps (NETs) [40] to capture microbes extracellularly and
autophagy to digest them intracellularly [41,42]. Several factors decide which antibacterial effec-
tor functions are activated: (i) the presence of serum favors phagocytosis but inhibits the forma-
tion of NETs [43], (ii) transmigration triggers the release of contents from secretory vesicles and
specific granules, and (iii) cell adherence lowers the threshold for integrin-dependent neutrophil
activation. Importantly, intravital microscopy imaging approaches have expanded our under-
standing of neutrophil–pathogen interactions extensively. A recent study using this technology
showed that phagocytosis and NETosis act in concert to combat Staphylococcus aureus in vivo,
supporting a novel “neutrophil multitasking” concept in host–pathogen interactions [44]. Other
in vivo studies demonstrated intracapillary neutrophil crawling in S. aureus infection [45] and
dynamic and intravascular NET formation in bacterial [46] and viral infections [47]. Fig. 1
illustrates the diversity of neutrophil effector mechanisms in host–pathogen interactions.
In the paragraphs below, the key neutrophil effector functions are discussed.
Phagocytosis
Neutrophils are rapid and potent phagocytes. Upon ligation of opsonic receptors, such as Fcγ
receptors, C-type lectins or complement receptors, the neutrophil membrane engulfs a particle
or a microbe, a process that is mediated by a complex interplay of membrane lipids, intracellu-
lar signalling cascades, and cytoskeletal rearrangements. Subsequently, primary and secondary
granules fuse with the phagosome and discharge their antimicrobial contents. Phagocytosis oc-
curs within minutes and is enhanced by the complement system, IgG antibodies, and cell pre-
activation. Once specific granules fuse with the phagosome, the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase is assembled from the membrane-bound flavocyto-
chrome b558, consisting of p91
phox (phagocyte oxidase) and p22phox subunits, and the cyto-
plasmic components p47phox, p67phox, p40phox, and Rac. Potassium ion (K+) fluxes also occur
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in response to NADPH oxidase activation [48]. Reeves et al. hypothesised that K+, in turn, re-
leases granule proteases that mediate bacterial killing, suggesting that the NADPH oxidase re-
action mainly serves as an activator for proteases instead of being a microbicidal mechanism
itself [49], a concept that has been challenged [50], most recently by a study showing that serine
protease deficient human neutrophils show no impairment in killing bacteria [51]. The killing
of S. aureus can be restored in NADPH oxidase-deficient neutrophils by adding liposomes
loaded with glucose oxidase [52] or polyethylene glycol-conjugated D-amino acid oxidase [53],
which produces H2O2. In these systems, neutrophils were still able to kill bacteria even when
the NADPH oxidase was inactive. Moreover, inhibition of the NADPH oxidase does not im-
pair killing of S. pneumoniae [54], and NADPH oxidase-deficient neutrophils from chronic
granulomatous disease (CGD, see below) patients are still able to kill Escherichia coli, indicating
Fig 1. Neutrophil effector mechanisms. The mechanisms neutrophils employ to fight infections include phagocytosis, the release of various granule
components into the extracellular space or into the phagosome (mainly proteases, oxidants, antimicrobial peptides), and the formation of neutrophil
extracellular traps (NETs).
doi:10.1371/journal.ppat.1004651.g001
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additional microbicidal mechanisms independent of reactive oxygen species (ROS) production.
A recent study further shows the involvement of the nucleotide-binding oligomerisation do-
main (NOD)-like receptor family, pyrin domain-containing protein (NLRP) 3 inflammasome
in macrophage phagocytosis by demonstrating that activation of caspase-1 controls the phago-
somal pH by regulating the NADPH oxidase (NOX) 2 to control phagosome function in gram-
positive, but not gram-negative infections [55].
Neutrophil Extracellular Traps (NETs)
NET induction. The concept of NETosis was introduced in 2004 [40] as a novel mechanism
for neutrophils to release extracellular DNA traps, composed of decondensed chromatin, his-
tones, and granule proteins. This finding inspired a variety of studies employing different
NETosis-inducing agents, including bacteria, fungi, protozoa, viruses, platelets, nitric oxide do-
nors, and others. NET formation has been described as a novel form of cell death [56], involv-
ing the translocation of elastase from primary granules to the nucleus, where it cleaves specific
histones and leads to chromatin decondensation [57]. Other studies support the notion that
even viable neutrophils can form NETs, consisting of mitochondrial [58] or nuclear DNA, in a
rapid and non-lytic manner [44]. Neutrophils treated with NADPH oxidase inhibitors or cells
from CGD patients show impaired NET formation in response to phorbol-12-myristate-
13-acetate (PMA) or S. aureus [56], and CGD gene therapy restored NET formation [59], sug-
gesting that ROS are indispensable for NET formation. However, other studies suggested that
ROS involvement depends on the stimulus [60–63]. In addition to ROS, several other pathways
have been reported to be involved in NET formation, such as peptidyl arginine deiminase
(PAD) 4 [64], the Raf-MEK (mitogen-activated kinase/ERK kinase)-ERK (extracellular signal-
regulated kinase) pathway [65] and autophagy [66].
Microbial NETosis escape mechanisms. Pathogens have evolved a variety of mechanisms
to escape from host defence. One of these mechanisms is the expression of DNase to degrade
NETs. StreptococcalDNases render the bacteria resistant to NET-mediated killing [67–69].
Similar results have been obtained with other pathogens. However, the killing capacity of
NETs was questioned by a study showing that pathogens entrapped in NETs survived and re-
tained their ability to proliferate after being released from NETs [70], an issue requiring
further investigations.
NETs in pathological conditions. Although NET generation has been described initially as
an antimicrobial mechanism, recent data suggest that NETs could play a more important role
in autoimmune and autoinflammatory pathologies, such as vasculitis [71], lung injury [72,73],
atherosclerosis [74], rheumatoid arthritis [75,76], thrombosis [77–80], gout [81], and systemic
lupus erythematosus (SLE) [43,82]. Several strategies have been proposed to interfere with
NETs, particularly digestion of NET-DNA with DNase or targeting NET-associated proteins.
DNase is successfully used to treat patients with CF, and its beneficial effect may be due to
cleaving NETs [83,84]. Other approaches were so far mainly restricted to animal models and
require clinical studies to assess their therapeutic usefulness.
Several aspects of NET formation remain enigmatic [85]. Despite a large number of studies
demonstrating NET formation in vitro, our understanding of NET formation in vivo is limited.
Most studies used PMA to induce NETs, while the major driver(s) of NET formation under
(patho)physiological conditions remain poorly understood. A recent study suggests that partic-
ularly larger pathogens, such as fungal hyphae, induce NET formation [86]. Another open
question is why some neutrophils form NETs and others do not. This heterogeneity remains
enigmatic, but recent studies indicate that NET formation could be linked to olfactomedin
4 expression by a subset of neutrophils [87]. Moreover, the biological relevance of lytic/cell
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death-associated versus non-lytic/viable NET formation remains an open question [88]. While
viable and rapid NET formation has been established in mice, human studies are scarce, but
propose a role for this rapid NET formation mechanism in S. aureus infections [60]. Neutro-
phils have a relatively low content of mitochondrial DNA compared to nuclear DNA. Never-
theless, mitochondrial DNA is released following physiological stimuli and may represent a
distinct form of NET formation [58]. While there is evidence for an involvement of elastase,
PAD-4, and histone citrullination in NET formation, the precise cellular machinery leading to
NET release is incompletely defined. For example, how elastase escapes from primary granules
to reach the nucleus and what physical forces lead to propulsion of nucleic acids outside the
cells remain largely elusive. How important are NETs in comparison to other neutrophil effec-
tor functions with regards to bacterial killing? A recent study in Papillon-Lefèvre syndrome,
where neutrophils lack active serine proteases, such as elastase, showed that patient’s neutro-
phils failed to form NETs, but were fully competent to kill bacteria [51]. These data indicate
that serine proteases are essential for NET formation, but that NET formation, in turn, could
be dispensable for killing of certain bacteria. Further studies with more bacterial, fungal, and
viral pathogens are required to solve these issues.
Antimicrobial peptides
Antimicrobial peptides play a major role at epithelial barriers and are secreted into various
body fluids, such as sweat, alveolar lining fluid, milk, or intestinal mucus [89]. Most peptides in
human neutrophil granules, like bactericidal/permeability-increasing protein, α-defensins, and
cathelicidins, execute their microbicidal effects by disrupting bacterial membranes. Lactoferrin
and lipocalin inhibit microbial iron uptake, and lysozyme cleaves cell wall peptidoglycans. Be-
yond their antimicrobial activities, cathelicidins (or their processed cleavage product LL-37)
and α-defensins can also act as proinflammatory mediators and chemokine receptor agonists.
Antimicrobial peptides, released by neutrophils, are also associated to NETs [85], facilitating a
close interaction with NET-entangled pathogens.
Neutrophils and the Microbiome
The gut microbiome has attracted high interest in various fields of research and there is now
compelling evidence to support the notion that mucosal commensals regulate granulopoiesis
and neutrophil homeostasis at several levels. Prolonged antibiotic treatment leads to reduced
neutrophil numbers and germ-free animals present a severe neutropenia, indicating a close
and homeostatic link between microbiota and neutrophils [90–92]. While our understanding
of cellular and molecular mechanisms remains incomplete, the regulation of neutrophil ho-
meostasis by the microbiome seems to be mediated by structural features of bacteria that can
activate innate pattern recognition receptors, leading to increased neutrophil production
[93–95]. There is also emerging evidence that metabolites, such as short chain fatty acids, pro-
duced by gut commensals from dietary fibers, regulate neutrophil-mediated inflammation
through the chemoattractant receptor G protein-coupled receptor (GPR) 43 expressed at high
levels by neutrophils [96]. Dysbiosis (that is, altered microbiome composition) has been associ-
ated with increased incidence and severity of various chronic inflammatory diseases and cancer
[97,98], yet the interaction between microbiota and neutrophils in these conditions remains to
be established. Moreover, further studies are warranted to determine whether an altered micro-
biome induces changes in neutrophil phenotypes and functions and, vice versa, whether target-
ing neutrophils has an effect on the microbiome.
PLOS Pathogens | DOI:10.1371/journal.ppat.1004651 March 12, 2015 6 / 23
Neutrophil–Immune Cell Interactions
Neutrophils can interact with a variety of immune and non-immune cells at several levels, best
studied for dendritic cells (DCs), macrophages, natural killer (NK) cells, and T cells [99,100].
Particularly, neutrophils and DCs frequently co-localize at sites of infection and DCs were
found to capture neutrophils that have phagocytosed Leishmania and underwent apoptosis, a
novel mechanism, which is how this pathogen undermines adaptive immune responses
[101,102]. T helper 17 (Th17) cells orchestrate neutrophil recruitment by producing IL-17 and
the neutrophil chemoattractant CXCL8. Neutrophils, in turn, recruit Th17 cells via release of
the chemokines CCL20 and CCL2, resulting in a positive feedback loop between neutrophils
and Th17 cells [103]. In addition, neutrophils interfere with T-cell proliferation as neutrophilic
myeloid-derived suppressor cells (MDSCs). Neutrophils secrete the B-cell and plasma cell sur-
vival factors “B lymphocyte stimulator” (BLyS) [104] and “A proliferation-inducing ligand”
(APRIL) [105]. In turn, a subset of splenic B cells produces GM-CSF [106] that provides differ-
entiation signals for splenic neutrophils [107]. Human splenic neutrophils have been reported
to activate marginal zone B-cell class switching and T-cell-independent antibody production,
suggesting a distinct “B cell-helper neutrophil” phenotype [108]. However, these findings have
recently been challenged by another study in which neutrophils with characteristics of the pro-
posed “B cell-helper neutrophil” phenotype were not found in human spleens [109].
Murine and human studies indicate that distinct neutrophil phenotypes, initially identified
as low-density neutrophils in cancer patients, inhibit T and NK cell proliferation. In analogy to
monocyte subsets, those suppressive neutrophilic cells have been termed granulocytic/neutro-
philic MDSCs [110]. The precise cellular mechanism(s) by which MDSCs suppress T-cell re-
sponses, however, have not been fully defined, but studies indicate that arginase, ROS,
indoleamine 2,3-dioxygenase (IDO), Mac-1, PD-L1, and STAT3 might be involved [110–113].
Inter-species differences appear to exist, as mechanisms identified in mice do not seem to be al-
ways transferable to the human situation. Importantly, in systemic inflammation, a distinct
subset of activated CD62Ldim neutrophils was found to suppress T cell proliferation mediated
through a Mac-1-dependent mechanism [114].
Neutrophil Defects
Inherited neutrophil defects exemplify the importance of this cell type for various infectious
and non-infectious conditions. These defects comprise severe congenital neutropenia (SCN),
cyclic neutropenia, CGD, leukocyte adhesion deficiencies (LADs), myeloperoxidase (MPO) de-
ficiency, warts, hypogammablogulinaemia, infections, myelokathexix (WHIM) syndrome, spe-
cific granule deficiency, defects in toll-like receptor (TLR)/interleukin 1 receptor-associated
kinase (IRAK) 4/caspase activation and recruitment domain-containing protein (CARD) 9 sig-
nalling, and other less defined entities and are summarized in the chapters below.
Severe congenital neutropenia (SCN)
In SCN, neutrophilic differentiation is blocked at the promyelocyte/myelocyte stage, leading to
isolated neutropenia with frequent severe bacterial and fungal infections and requiring lifelong
treatment with G-CSF. Upon G-CSF treatment, SCN patients produce low numbers of neutro-
phils, sufficient to protect them from infections. The majority of SCN patients harbour autoso-
mal dominant mutations in the neutrophil elastase gene (ELANE) [115]. Mechanistically, it has
been proposed that intracellular accumulation of misfolded mutated neutrophil elastase acti-
vates the unfolded-protein response (UPR) and endoplasmatic reticulum (ER) stress [116,117]
and promotes apoptosis [118]. Beyond ELANE, mutations in the haematopoietic cell-specific
Lyn substrate (HCLS) 1-associated gene X1 (HAX1) were identified as a cause of neutropenia
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[119]. Further studies showed that the HAX1 interaction partner HCLS1 is activated by
G-CSF, leading to the activation of the myeloid-specific transcription factor lymphoid enhanc-
er binding factor (LEF)-1 [120,121]. A small subgroup of SCN patients have mutations in the
transcriptional repressor oncoprotein growth factor independent (GFI) 1 [122], cytoskeletal
regulator Wiskott-Aldrich Syndrome (WAS) protein [123], glucose-6 phosphatase catalytic
subunit 3 (G6P3C) [124], endosomal adaptor protein p14 (also known as MAPBPIP) [125], or
the endosomal trafficking vacuolar protein sorting 45 (VPS45) [126]. Depending on the type of
the inherited gene mutation, SCN patients exhibit either isolated neutropenia (ELANEmuta-
tions) or additional syndromes such as lymphopenia (GFI1 gene mutations); monocytopenia
(WAS-mutations); mental retardation/seizures (HAX1 mutations); prominent superficial ve-
nous network, atrial defects, and uropathy (G6PC3-associated disorders); and albinism and
hyper-gammaglobulinemia (p14-mutated patients).
Chronic granulomatous disease (CGD)
CGD is caused by mutations in the genes encoding the subunits of the phagocyte NADPH oxi-
dase complex, with an incidence around 1/200,000 [127]. CGD phagocytes cannot effectively
produce superoxide (O2
-) and fail to kill ingested pathogens, leading to severe infections, main-
ly by Staphylococcus and Aspergillus species [127,128]. CGD disease severity correlates inverse-
ly with the remaining neutrophil ROS production capacity [129]. The majority of CGD
patients show mutations in gp91phox, which is the only CGD gene encoded on the X-chromo-
some [127–131]. X-linked CGD is characterised by an early onset and a high morbidity and
mortality [128,129] and can also affect female carriers with an extreme X-chromosome inacti-
vation pattern [132]. It has been proposed that the susceptibility of CGD patients to Aspergillus
species might be due to a defect in ROS-dependent NET formation [59], an issue requiring fur-
ther research. CGD patients exhibit a state of chronic immune activation, possibly due to
diminished autophagy triggering excessive IL-1β release [133]. As a result, autoimmune condi-
tions, such as SLE, discoid lupus erythematosus, and rheumatoid arthritis, are more prevalent
among CGD patients [127,128,134]. Obstructive gastrointestinal and genitourinary granulo-
mas in CGD are usually not caused by infections but by chronic inflammation [135] and often
coincide with colonic inflammation reminiscent of Crohn’s disease [127,128,136]. This may be
due to diminished intestinal epithelial defence as a result of the lack of ROS production by
transmigrating CGD neutrophils [137].
Leukocyte adhesion deficiencies (LADs)
LADs are caused by several autosomal recessive genetic defects in molecules involved in the
leukocyte adhesion cascade. The patients’ neutrophils cannot leave the circulation, leading to
infection susceptibility [138]. In LAD-I, mutations in the gene encoding CD18, the integrin
β2-chain, lead to the complete absence or decreased expression of the integrins αLβ2, αMβ2,
αXβ2, and αDβ2 [139–143], rarely to normally expressed, but dysfunctional, β2-integrins
[144]. Mutations in a Golgi guanosine diphosphate-fucose transporter (GFTP) protein, which
is encoded by the SLC35C1 (solute carrier family 35 member C1) gene, lead to LAD-II
[145,146], which was reclassified as the congenital disorder of glycosylation-IIc (CDG-IIc)
[147]. Patients with LAD-II develop milder infections as in LAD-I, but have other abnormali-
ties [147–149]. LAD-III, also known as LAD-I/variant, is caused by mutations in the gene
FERMT3 (fermintin family homolog 3) encoding the β-integrin (β1, β2, and β3) adaptor pro-
tein kindlin-3. LAD-III patients also suffer from platelet defects and subsequent bleeding as
well as osteopetrosis-like bone defects [150–154]. A combination of a LAD-like and CGD-like
phenotype was described in two patients with mutations in Rac2 in which neutrophils showed
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defective chemotaxis due to impaired actin polymerisation and impaired NADPH oxidase acti-
vation [155,156]. An exciting, novel concept has recently emerged from studies of LAD-I pa-
tients in which defective neutrophil recruitment causes inflammatory periodontal bone loss.
Surprisingly, the severe bone loss in these patients was not due to a lack of control of bacterial
infections, but rather to the inability to control IL-17 production, which is normally reduced
by phagocytosis of locally recruited neutrophils [157]. These findings suggest that neutrophils,
the prototypic proinflammatory cells, have a profound anti-inflammatory function in steady
state that is mediated by their effective efferocytosis. Thus, neutralizing IL-17 may be relevant
for LAD-I and other diseases in which neutrophil recruitment to peripheral tissues is defective.
WHIM syndrome
In WHIM syndrome, CXCR4 gain-of-function mutations lead to neutropenia caused by in-
creased retention of neutrophils in the bone marrow [158]. In addition to neutropenia, these
patients often have lymphopenia and monocytopenia. The concept of CXCR4-dependent re-
lease of neutrophils from the bone marrow has recently been challenged by an intravital mi-
croscopy study showing that CXCR4 inhibition using plerixafor in mice triggers mobilization
of neutrophils from the marginated pool of the lung and simultaneously prevents neutrophil
homing to the bone marrow [27], highlighting the lung as a rich and easily mobilized source of
neutrophils. The therapeutic relevance of these findings for neutropenic patients and other dis-
eases remains to be defined in future studies.
Defects in innate immune receptor signalling
Neutrophils express various TLRs and TLR activation triggers antibacterial effector functions
[159]. Mutations in myeloid differentiation primary response (MYD) 88 or IRAK4, central
downstream mediators of TLR signalling, lead to recurrent, invasive bacterial infections in in-
fancy and early childhood. This susceptibility decreases with age, so TLR-mediated signalling
in neutrophils seems rather dispensable beyond adolescence. Neutrophils of these patients do
not respond to TLR and IL-1R ligation, whereas ROS production is normal [160,161]. Acute-
phase responses are delayed or even absent despite severe infections [162–166]. Mutations in
CARD9, a protein essential for the sensing of fungi, lead to Candida infections [167], which
was recently linked to impaired neutrophil killing [168]. Mutations in proteins regulating the
activity of nuclear factor (NF)κB, namely NFκB essential modulator (NEMO) and inhibitor of
NFκB kinase (IKK)α, lead to immunodeficiency in combination with other symptoms [166].
Specific Granule and MPO deficiency
Patients with specific-granule deficiency are extremely rare and suffer from recurrent bacterial
infections due to a lack of secondary and tertiary granule proteins [169]. Specific-granule defi-
ciency is caused by mutations in the transcription factor CCAAT/enhancer-binding protein
ε (cEBPε), which is an important transcriptional regulator of granulopoiesis at the late stages
of differentiation. Inherited MPO deficiency is frequent in humans, but MPO-deficient indi-
viduals are mostly asymptomatic, except for a small subset that suffers from diabetes [170].
Neutrophils in Acute Inflammation
Neutrophils are the first cells recruited to sites of infection and inflammation and, therefore,
play a key role in several forms of acute inflammation, a topic that goes beyond the scope of
this review. Here, we highlight several recent findings in this field and refer for further informa-
tion to previous, more comprehensive reviews [171–174]. Neutrophil recruitment and
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activation are key events in acute inflammatory conditions, such as acute lung injury, and es-
sential to provide a first cellular shield against bacterial and fungal pathogens. Neutrophil infil-
tration is not limited to infectious conditions and also occurs in sterile environments, mediated
by a multistep migratory sequence, involving the inflammasome, chemokines, and formyl-pep-
tide signals [175]. Physiologically, acute neutrophilic inflammation is followed by a resolution
phase [176], important for tissue homeostasis. If these resolving mechanisms fail, neutrophils
drive chronic inflammation, characterized by oxidant and protease release and leading to tissue
injury. Consequently, a precise understanding of the local fine-tuning of neutrophil activation
at sites of inflammation is mandatory. Full-blown neutrophil activation generally requires a
two-step process, initiated by preactivation/priming through proinflammatory cytokines, such
as tumor necrosis factor (TNF) α, IL-1β, IL-8, leukotriene (LT)B4 or GM-CSF, or bacterial
products and by a later second-hit stimulus [177]. Priming is not a terminal event, as neutro-
phils can undergo cycles of priming and de-priming [178]. Importantly, the lung has been
demonstrated recently to be a place for retention of primed neutrophils, a protective mecha-
nism shown to be impaired in acute respiratory distress syndrome (ARDS) [28,179]. While
various stimulants of neutrophil activity have been established, negative regulators are poorly
defined. A recent study demonstrates that the sialic acid binding Ig-like lectin E (siglec-E) acts
as an important negative regulator of neutrophil recruitment to the lung [180]. The NADPH
oxidase, well known as the major source of ROS, has paradoxically also been shown to limit in-
flammation [134], yet the underlying mechanisms remained poorly defined. Davidson and co-
workers now show that the NADPH oxidase dampened neutrophilic inflammation and was
protective against acute lung injury by activating nuclear factor erythroid 2-related factor 2
(Nrf2), a transcriptional factor inducing antioxidative and cytoprotective pathways and sug-
gesting Nrf2 as a novel anti-inflammatory therapeutic target [181]. Other recently described
mechanisms in acute neutrophilic inflammation include the pulmonary endothelial glycocalyx
[182] and myeloid-related protein-14 [183] in sepsis, midkine [184], hematopoietic progenitor
kinase 1 (HPK1) [185], and chitinase-like proteins [186].
Neutrophils in Chronic Disease and Tissue Injury
While the role of neutrophils in acute inflammation is rather well established, their complexity
in chronic diseases, tissue injury, and repair has just begun to evolve. Several chronic inflam-
matory disease conditions are characterized by a sustained influx of neutrophils, such as CF,
chronic obstructive pulmonary disease, rheumatoid arthritis, nephritis, SLE, and cardiovascu-
lar diseases. Chemokines, lipid mediators, complement fragments, and tissue breakdown prod-
ucts trigger the migration of neutrophils into diseased tissues. Upon local activation,
transmigrated neutrophils release their toxic ingredients, proteases and oxidants, which cause
tissue injury and drive the production of chemokines that feed into the neutrophil recruitment
loop. Neutrophil-derived serine and matrix metalloproteases (MMPs) cleave extracellular ma-
trix (ECM; elastin and collagen) and impair host defence by degrading immune receptors and
collectins. Neutrophils are a prominent source of MMPs, particularly MMP-9, thereby contrib-
uting to tissue damage and remodelling [187]. Consequently, neutrophil activities lead to cleav-
age of ECM into small fragments that, in turn, can stimulate the immune system and feed a
positive feedback loop of tissue destruction and immune cell infiltration. Central to tissue inju-
ry and repair circuits is the tripeptide proline–glycine–proline (PGP), which is generated
through the concerted action of several neutrophil-derived proteases, particularly MMP-8,
MMP-9, and prolyl endopeptidase (PE). PGP can act as a chemokine mimetic and triggers neu-
trophil migration through CXCR1 and CXCR2 [188]. PGP is inactivated through a non-
canonical functionality of the enzyme leukotriene A4 hydrolase (LTA4H) [189]. Persistence of
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PGP has been found in several neutrophilic diseases, including CF lung disease. Another neu-
trophil-derived protein involved in inflammation and tissue remodeling is high mobility group
box protein-1 (HMGB1), a chromatin protein released from necrotic neutrophils and activat-
ing receptor for advanced glycation endproducts (RAGE) TLR and CXCR4 [190,191].
Neutrophil Heterogeneity and Plasticity
Heterogeneity of neutrophils is found at several levels: (i) nuclear appearance (band cells, ma-
ture and hypersegmented neutrophils); (ii) density (“low”-MDSCs versus “high” conventional
density neutrophils [192]); (iii) NET-releasing versus non-NET-releasing neutrophils; and (iv)
receptor expression profiles associated with distinct neutrophil subsets, which are summarized
below:
• Olfactomedin 4-expressing neutrophils, associated with a NET-releasing neutrophil subtype
[87]
• CD177 (NB1)-expressing neutrophils, associated with proteinase 3 and autoimmune diseases
[193]
• CD16brightCD62Ldim for suppressive neutrophils in systemic inflammation [114]
• CD66b/CD33-expressing low-density neutrophils for neutrophilic MDSCs [192]
• CXCR4+ for aged/senescent neutrophils [194]
• CD63-expressing neutrophils in the airways of patients with CF [195]
• CD49d-expressing neutrophils in atopic individuals [196]
• VEGF-induced MMP-9 expressing “pro-angiogenic” neutrophils [187]
• Neutrophils expressing a T-cell receptor-associated variable immunoreceptor complex [197]
• ICAM-1/CD54-expressing neutrophils associated with systemic inflammation and reverse
migration [23,198]
• N1/N2 tumor-associated neutrophils (TANs) in murine tumor models (antitumorigenic,
proinflammatory N1 neutrophils; protumorigenic, immunosuppressive N2 neutrophils)
[199]
• PMN-I (producing IL-12 and CCL3, inducing classically-activated macrophages) conferring
protection against methicillin-resistant S. aureus (MRSA) infection and PMN-II (producing
IL-10 and CCL2, inducing alternatively-activated macrophages) conferring susceptibility for
MRSA infection [200]
The disease associations and functional characteristics of these described neutrophil pheno-
types remain to be established. Could these markers be useful for subtyping different harmful
versus beneficial neutrophil subsets at sites of chronic inflammation? Further studies in hu-
mans and mouse models are required to link phenotypic characteristics with functions.
Beyond heterogeneity, the potential of neutrophils to undergo phenotypic and/or functional
plasticity has been addressed by some studies, demonstrating that neutrophils can transdiffer-
entiate into: (i) DC-neutrophil hybrids upon GM-CSF stimulation with phenotypic and func-
tional characteristics of both neutrophils and DCs [201,202]; (ii) DC-like cells in rheumatoid
arthritis [203]; (iii) MHC-II-expressing antigen-presenting cells, induced by acidosis, cyto-
kines, and growth factors and found in chronic inflammatory diseases [204,205]; and (iv) giant
phagocytes, associated with autophagy [206]. Moreover, under inflammatory conditions,
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band-stage neutrophils were recently shown to transdifferentiate into monocytes [207]. Meta-
bolic reprogramming, including the induction of anabolic pro-survival pathways, has been de-
scribed in CF airway neutrophils, including up-regulation of the mammalian target of
rapamycin (mTOR) pathway [208] and nutrient/glucose transporters [209]. Monocytic
MDSCs have been shown to transdifferentiate into neutrophilic MDSCs [210]. While some of
these neutrophil transdifferentiation phenotypes are found in chronic inflammatory and infec-
tive disease conditions [100,203,208], their overall disease relevance remains to be
better defined.
Conclusions
Novel technologies, such as intravital microscopy and transgenic mice, have expanded our in-
sights into neutrophil homeostasis and effector functions tremendously. Neutrophil steady-
state homeostasis is not only regulated by growth factors, cytokines, and chemokines, but also
involves microbial pattern recognition, linking hematopoiesis with microbiota. Neutrophil
clearance seems to be even more complex, involving apoptosis/efferocytosis, reverse migration,
and homing of senescent neutrophils back to the bone marrow, a process that, in turn, may
regulate circadian neutrophil turnover. Besides their role as potent phagocytes, neutrophils ex-
pose their granule contents and DNA through NETosis, but its precise pathophysiological rele-
vance in vivo remains to be defined. The spectrum of neutrophil plasticities has been further
expanded by their role as immunomodulatory MDSCs that dampen T-cell activity. The clinical
importance of neutrophils in host defence is underscored by the severity and complexity of in-
fections in patients with inherited immunodeficiencies associated with a loss of neutrophil
number or function. Faced with the emerging heterogeneity and plasticity of neutrophils, the
challenge for the future remains how to target harmful, while promoting protective, neutrophil
phenotypes. Based on these concepts, neutrophils in chronic inflammatory disease conditions
are supposed to do more harm than good, rendering them promising therapeutic targets in
chronic diseases. However, targeting neutrophils always bears the risk of increasing infection
susceptibility, particularly towards bacterial and fungal pathogens. Small-molecule CXCR2 an-
tagonists inhibit neutrophil chemotaxis and have been used in clinical studies in CF lung dis-
ease, with limited success [211]. Beyond these universal targeting approaches, inhibiting or
depleting specific harmful neutrophil subsets, while preserving beneficial subtypes, would be
preferential. However, this approach is limited by our current understanding of neutrophil het-
erogeneity. Which markers could be useful to identify harmful neutrophil phenotypes? Future
studies using small molecules or antibodies targeting distinct neutrophil subsets will be re-
quired to address this question and to move forward towards a neutrophil subtype-selective
pharmacologic treatment strategy.
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